About the product

Lifelight turns smartphones* into BP monitoring devices that can be embedded into any native app.

Helping to fight Europe’s biggest killer

High blood pressure, or hypertension, is the leading preventable risk factor for cardiovascular disease and mortality worldwide.⁵ In England it is estimated that for every 10 people diagnosed with hypertension another 7 remain undiagnosed and untreated.⁸

By making it easy for everyone to check and MEASURE their blood pressure, Lifelight can provide early detection of hypertension and help fight Europe’s biggest killer.

“Lifelight is estimated to save over £300m a year for NHS reinvestment, if used in GP surgeries alone”.

JB Medical – Independent NHS Healthcare Economist – click to view report.

Lifelight is unique:

No Contact

No Hardware

No hardware

No Calibration

Easily integrated

Fully scalable

No white coat syndrome

No discomfort of the cuff

No white coat syndrome

no logistics

No Logistics

clinically validated

Improving efficiency and saving money

Lifelight can reduce workload pressure in primary and secondary care environments through:

Fewer care home and home visits

The average GP surgery makes 27 home and 13 care home visits every week.² Lifelight can be made available to frequent users of either service to reduce need and ensure that time spent is used more effectively where they do take place.

Reduced anxiety

‘White coat’ syndrome affects up to 30% of the population³ and can cause blood pressure to increase due to the stress of being in a medical setting. Lifelight can help reduce this anxiety and generate savings of up to £10.5m⁴ by removing the need for a cuff.

Health data captured easily and quickly

Use Lifelight measurements alongside other data captured in your platform to achieve desired outcomes.

Why Lifelight? Reasons to believe:

Why Lifelight?
Reasons to believe:

Clinically Validated Performance

Lifelight has been assessed in eight different clinical trials over the last five years and has been published in several cardio publications.

All age groups and blood pressure ranges included

Lifelight research included spot-check estimates of adult patients (paediatric use in roadmap).We also tested at the extremes of hyper/hypo tension.¹⁰

Secure data processing

Lifelight anonymises data and processes it in the cloud to ensure greater security.

Applicable to all

Lifelight can be used for all skin tones as determined by the Fitzpatrick skin type scale.⁶

Already used in clinical environments

Lifelight is being used by the UK’s National Health Service and is available to 1,700 primary care practices as a ‘software as a service’.

Technology is mature

Lifelight has taken over seven years to develop, achieved four international patents (with more pending) and is the subject of seven peer reviewed papers.

Regulatory Approved

Lifelight has CE Class IIa device status under EU MDR for BP and pulse.⁷

Uses tech the user already owns

Lifelight works on mobile devices.*

References

¹ Claire Blacklock et al. From research paper When and how do GPs record vital signs in children with acute infections?: e679 British Journal of General Practice, October 2012
² Betty Baird et al. Understanding pressures in general practice: Page 16, The Kings Fund > Ideas that change health care May 2016
³ Eoin O'Brien et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society

BMJ 2000 Apr 22;320(7242):1128–1134.
⁴ Matthew R. Weir, Edgar V. Lerma: Chronic Kidney Disease and Hypertension, page 113 - 201

5
⁵ Mills KT, et al. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–237. 

⁶ Heiden, et al. Measurement of vital signs using Lifelight remote photoplethysmography: Results of the VISION-D and VISION-V observational studies. JMIR Form Res. 2022;6:e36340.
⁷ EU Quality Management System Certificate No. G15 103940 0003

⁸ NICE Clinical Knowledge Summaries. Hypertension. Available at: https://cks.nice.org.uk/topics/hypertension/background-information/prevalence/. Last accessed May 2025.

⁹ Misra, et al. The measurement of vital signs in pediatric patients by Lifelight software in comparison to the standard of care: Protocol for the VISION-Junior observational study. JMIR Res Protoc. 2025;14:e58334.

¹⁰Kapoor, et al. Contactless and calibration-free blood pressure and pulse rate monitor for screening and monitoring of hypertension: Cross-sectional validation study. JMIR Cardio. 2024;8:e57241.

References

¹ Claire Blacklock et al. From research paper When and how do GPs record vital signs in children with acute infections?: e679 British Journal of General Practice, October 2012
² Betty Baird et al. Understanding pressures in general practice: Page 16, The Kings Fund > Ideas that change health care May 2016
³ Eoin O'Brien et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society

BMJ 2000 Apr 22;320(7242):1128–1134.
⁴ Matthew R. Weir, Edgar V. Lerma: Chronic Kidney Disease and Hypertension, page 113 - 201

5
⁵ Mills KT, et al. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–237. 

⁶ Heiden, et al. Measurement of vital signs using Lifelight remote photoplethysmography: Results of the VISION-D and VISION-V observational studies. JMIR Form Res. 2022;6:e36340.
⁷ EU Quality Management System Certificate No. G15 103940 0003

⁸ NICE Clinical Knowledge Summaries. Hypertension. Available at: https://cks.nice.org.uk/topics/hypertension/background-information/prevalence/. Last accessed May 2025.

⁹ Misra, et al. The measurement of vital signs in pediatric patients by Lifelight software in comparison to the standard of care: Protocol for the VISION-Junior observational study. JMIR Res Protoc. 2025;14:e58334.

¹⁰Kapoor, et al. Contactless and calibration-free blood pressure and pulse rate monitor for screening and monitoring of hypertension: Cross-sectional validation study. JMIR Cardio. 2024;8:e57241.

References

¹ Claire Blacklock et al. From research paper When and how do GPs record vital signs in children with acute infections?: e679 British Journal of General Practice, October 2012
² Betty Baird et al. Understanding pressures in general practice: Page 16, The Kings Fund > Ideas that change health care May 2016
³ Eoin O'Brien et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society

BMJ 2000 Apr 22;320(7242):1128–1134.
⁴ Matthew R. Weir, Edgar V. Lerma: Chronic Kidney Disease and Hypertension, page 113 - 201

5
⁵ Mills KT, et al. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–237. 

⁶ Heiden, et al. Measurement of vital signs using Lifelight remote photoplethysmography: Results of the VISION-D and VISION-V observational studies. JMIR Form Res. 2022;6:e36340.
⁷ EU Quality Management System Certificate No. G15 103940 0003

⁸ NICE Clinical Knowledge Summaries. Hypertension. Available at: https://cks.nice.org.uk/topics/hypertension/background-information/prevalence/. Last accessed May 2025.

⁹ Misra, et al. The measurement of vital signs in pediatric patients by Lifelight software in comparison to the standard of care: Protocol for the VISION-Junior observational study. JMIR Res Protoc. 2025;14:e58334.

¹⁰Kapoor, et al. Contactless and calibration-free blood pressure and pulse rate monitor for screening and monitoring of hypertension: Cross-sectional validation study. JMIR Cardio. 2024;8:e57241.

Product images shown on our website are for illustrative purposes only and not an exact representation of the product.
* Lifelight is compatible with a range of validated mobile devices. Please contact us for a complete list.

Talk to us today

Lifelight is available NOW to insurers, pharma and medtech companies and healthcare providers including the NHS.


Contact us to get details on integrating Lifelight into your healthcare app.

Enough of the cuff!

Contact Information

The University of Southampton Science Park

2 Venture Road, Chilworth

Southampton, Hampshire

SO16 7NP

Follow us on LinkedIn

© Copyright 2025 | www.lifelight.ai is owned by xim Ltd. trading as Lifelight.

Lifelight is a CE Class IIa Medical Device under the EU MDR. Lifelight® and its accompanying logo mark are registered trademarks of xim Limited.

Talk to us today

Lifelight is available NOW to insurers, pharma and medtech companies and healthcare providers including the NHS.


Contact us to get details on integrating Lifelight into your healthcare app.

Enough of the cuff!

Contact Information

The University of Southampton Science Park

2 Venture Road, Chilworth

Southampton, Hampshire

SO16 7NP

info@lifelight.ai

Follow us on LinkedIn

© Copyright 2025 | www.lifelight.ai is owned by xim Ltd. trading as Lifelight.

Lifelight is a CE Class IIa Medical Device under EU MDD and UK MDR. Lifelight® and its accompanying logo mark are registered trademarks of xim Limited.

Talk to us today

Lifelight is available NOW to insurers, pharma and medtech companies and healthcare providers including the NHS.


Contact us to get details on integrating Lifelight into your healthcare app.

Enough of the cuff!

Contact Information

The University of Southampton Science Park

2 Venture Road, Chilworth

Southampton, Hampshire

SO16 7NP

info@lifelight.ai

Follow us on LinkedIn

© Copyright 2025 | www.lifelight.ai is owned by xim Ltd. trading as Lifelight.

Lifelight is a CE Class IIa Medical Device under EU MDD and UK MDR. Lifelight® and its accompanying logo mark are registered trademarks of xim Limited.